Search

everythinglearnresearchcommunity

for

Search:↓

Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.

B cells can both help and hinder the body's defense against melanoma.

Alopecia areata shows a unique type 1 interferon signature, suggesting potential treatment by targeting this pathway.

Natural killer cells play a key role in autoimmune skin diseases like pemphigus vulgaris.

Myeloid-derived suppressor cells help control autoimmune cells and promote hair regrowth in alopecia areata.

Allergies, especially dust mite allergy, may worsen alopecia areata, and desensitization could help reduce its severity.

γδ T cells adapt uniquely to different tissues in mice.

Some people with chronic hair loss may have thyroid autoimmunity.

People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.

PD‐L1 and PD‐L2 may not effectively control immune activation in alopecia areata.

Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.

The model showed that immune system guardians and the cytokine interferon-γ are key in alopecia areata progression.

ILC1-like cells may contribute to hair loss in alopecia areata.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Certain genetic variants linked to immune response increase the risk of alopecia areata in Taiwanese people.

Blocking CD44 can reduce leukocyte migration in autoimmune skin diseases.

A man developed autoimmune symptoms after the Pfizer COVID-19 vaccine, highlighting the need for thorough vaccine safety checks.

Alopecia areata is linked to autoimmune antibodies.

Biopsy can differentiate between alopecia areata and androgenic alopecia, and if more information is needed, testing for CD3 and CD8 can help.

IL-27 may help prevent hair loss by creating immune-suppressing cells.

CD8+ virtual memory T cells may cause hair loss in alopecia areata.

Regulatory T cells protect hair follicle stem cells by maintaining immune privilege in the skin.

New treatments for alopecia areata may target specific immune cells and pathways involved in hair loss.

AHST shows promise for treating type 1 diabetes but needs more research before widespread use.

Arg1+ macrophages may play a role in causing alopecia areata.

Targeting CD200 could be a new treatment for rheumatoid arthritis.

Targeting the AhR pathway may help treat alopecia areata.

Thymoma with alopecia areata may be linked to abnormal immune cells.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.